Natera, Inc. $NTRA Shares Sold by Zevenbergen Capital Investments LLC

Key Points

• Zevenbergen Capital Investments LLC reduced its stake in Natera, Inc. by 5.5% during the 2nd quarter, now holding 405,982 shares valued at approximately $68.59 million.
• Insider transactions included sales by Director Gail Boxer Marcus and Solomon Moshkevich, with a combined total of over $800,000 in shares sold, indicating a notable decrease in their ownership.
• Natera, Inc. reported earnings results that missed analyst expectations, posting a loss of ($0.74) per share despite revenue growth of 32.2% year-over-year, totaling $546.60 million.

Zevenbergen Capital Investments LLC decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 5.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 405,982 shares of the medical research company's stock after selling 23,683 shares during the period. Natera comprises 1.3% of Zevenbergen Capital Investments LLC's portfolio, making the stock its 22nd largest holding. Zevenbergen Capital Investments LLC owned about 0.30% of Natera worth $68,587,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in NTRA. Focus Partners Wealth raised its position in Natera by 35.4% in the fourth quarter. Focus Partners Wealth now owns 5,519 shares of the medical research company's stock worth $874,000 after acquiring an additional 1,442 shares during the period. Lazard Asset Management LLC raised its position in Natera by 22.0% in the fourth quarter. Lazard Asset Management LLC now owns 3,052 shares of the medical research company's stock worth $482,000 after acquiring an additional 551 shares during the period. OMERS ADMINISTRATION Corp raised its position in Natera by 53.7% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 6,300 shares of the medical research company's stock worth $997,000 after acquiring an additional 2,200 shares during the period. Nuveen Asset Management LLC raised its position in Natera by 0.8% in the fourth quarter. Nuveen Asset Management LLC now owns 583,119 shares of the medical research company's stock worth $92,308,000 after acquiring an additional 4,855 shares during the period. Finally, Quantinno Capital Management LP bought a new position in Natera in the fourth quarter worth approximately $373,000. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other news, Director Gail Boxer Marcus sold 4,299 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the sale, the director owned 8,118 shares of the company's stock, valued at $1,358,628.48. This represents a 34.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total transaction of $500,310.00. Following the sale, the insider directly owned 130,205 shares of the company's stock, valued at $21,714,287.85. The trade was a 2.25% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,423 shares of company stock worth $8,459,656. Insiders own 5.63% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NTRA. Morgan Stanley reissued an "overweight" rating and issued a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Barclays reissued an "overweight" rating and issued a $210.00 price objective (up from $190.00) on shares of Natera in a research note on Friday, August 8th. Piper Sandler reaffirmed an "overweight" rating and set a $220.00 target price (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, Cowen reaffirmed a "buy" rating on shares of Natera in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $194.00.

Natera Price Performance

NASDAQ:NTRA traded up $1.57 during trading hours on Friday, hitting $181.43. 269,151 shares of the company were exchanged, compared to its average volume of 1,446,937. The stock has a market capitalization of $24.90 billion, a price-to-earnings ratio of -94.98 and a beta of 1.68. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $183.00. The company's 50 day moving average price is $156.38 and its 200-day moving average price is $154.77.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. The business's revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.